The effect of hormone replacement therapy on diastolic left ventricular function in hypertensive and normotensive postmenopausal women.
OBJECTIVE
To evaluate the effect of hormone replacement therapy (HRT) on left ventricular diastolic function in a group of hypertensive and normotensive postmenopausal women.


METHODS
Left ventricular diastolic function at rest was evaluated by M-mode, two-dimensional and Doppler echocardiography in 19 postmenopausal women with normal blood pressure and 11 postmenopausal women with mild hypertension, before treatment and during 12 months of HRT. Transdermal estradiol was used in women with a surgical menopause and a sequential regimen of transdermal estradiol and peroral medroxyprogesterone acetate in women with a spontaneous menopause. The parameters assessed were: body mass index, heart rate, ejection fraction of the left ventricle (EF), septal (SW) and posterior wall (PW) dimensions, left ventricular end-systolic (LVsd) and end-diastolic (LVdd) dimensions and volumes (ESV, EDV), total diastolic time (DT), duration of the early (Ei) and of the late (Ai) filling phase, peak velocity of the early (E) and late mitral flow (A), A/E velocity ratio and systolic and diastolic blood pressure. Quantitative data were analyzed using unpaired t-test, MANOVA and multiple regression analysis where appropriate.


RESULTS
Hypertensive postmenopausal women had significantly higher SW (P < 0.05), PW (P < 0.05), A/E (P < 0.05) and A (P < 0.001) than normotensive postmenopausal women, before therapy. After 12 months of HRT a significant decrease in SW, PW, LVsd, ESV and increase in EF, DT, Ei and E was observed in both hypertensive and normotensive postmenopausal women. Heart rate slowed and systolic pressure decreased significantly only in normotensive postmenopausal women on HRT.


CONCLUSIONS
HRT of 12 months' duration does not deteriorate left ventricular diastolic function of both hypertensive and normotensive postmenopausal women. Improvement in some parameters of diastolic function could be partially explained by the decrease in heart rate and systolic pressure, induced by therapy.
Beljic
T
T
Department of Medicine, Zvezdard University Medical Centre, Belgrade, Yugoslavia.
Babic
D
D
Marinkovic
J
J
Prelevic
G M
GM
D000279:Administration, Cutaneous; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002979:Climacteric / Q000187:drug effects* / Q000502:physiology; D003971:Diastole / Q000187:drug effects* / Q000502:physiology; D004958:Estradiol / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000503:physiopathology*; D008137:Longitudinal Studies; D008594:Menopause, Premature / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology
D004958:Estradiol